This observation has raised concerns regarding suboptimal drug exposure, altered pharmacokinetics, and heightened inflammatory burden in obese patients, highlighting the potential need for dose optimization or alternative treatment strategies in this population (63, 64)
184 ThiedigK.WeisshaarB.StrackeR
The long-term safety and sustained efficacy of PT-141 was demonstrated in the 52-week open-label extension of the RECONNECT trials
Older adults often have a reduced thirst sensation, and GLP-1 medications may further decrease thirst
While bupropion itself may contribute to weight loss as a secondary effect, which could theoretically complement the weight management goals of Saxenda, this potential benefit remains largely theoretical without robust UK-based clinical evidence
Can I use oral tirzepatide instead of injections to reduce diarrhea